Literature DB >> 21493964

The extent of left ventricular scar quantified by late gadolinium enhancement MRI is associated with spontaneous ventricular arrhythmias in patients with coronary artery disease and implantable cardioverter-defibrillators.

Paul A Scott1, John M Morgan, Nicola Carroll, David C Murday, Paul R Roberts, Charles R Peebles, Stephen P Harden, Nick P Curzen.   

Abstract

BACKGROUND: Characterization of sudden cardiac death (SCD) risk remains a challenge in the application of implantable cardioverter-defibrillator (ICD) therapy. Late gadolinium enhancement cardiac MRI (LGE-CMR) can accurately identify myocardial scar. We performed a retrospective, single-center observational study to evaluate the association between the extent and distribution of left ventricular scar, quantified using LGE-CMR, and the burden of ventricular arrhythmias in patients with coronary artery disease and ICDs. METHODS AND
RESULTS: All patients included (2006 to 2009) had undergone LGE-CMR before ICD implantation. Scar (defined as myocardium with a signal intensity ≥50% of the maximum in scar tissue) was characterized in terms of percent scar, scar surface area, and number of transmural left ventricular scar segments. The end point was appropriate ICD therapy. Sixty-four patients (mean age, 66±11 years; male sex, 51) were included. During 19±10 months follow-up, appropriate ICD therapy occurred in 19 (30%) patients. In Cox regression analyses, both percent scar (hazard ratio per 10%, 1.75; 95% CI, 1.09 to 2.81; P=0.02) and number of transmural scar segments (hazard ratio per segment, 1.40; 95% CI, 1.15 to 1.70; P=0.001) were significantly associated with the occurrence of appropriate ICD therapy.
CONCLUSIONS: In this pilot study, the extent of myocardial scar characterized by LGE-CMR was significantly associated with the occurrence of spontaneous ventricular arrhythmias. We hypothesize that scar quantification by LGE-CMR may prove a valuable risk stratification tool for the occurrence of ventricular arrhythmias, which may have implications for patient selection for ICD therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21493964     DOI: 10.1161/CIRCEP.110.959544

Source DB:  PubMed          Journal:  Circ Arrhythm Electrophysiol        ISSN: 1941-3084


  33 in total

1.  Correlation between ECG abnormalities and cardiac parameters in highly trained asymptomatic male endurance athletes: evaluation using cardiac magnetic resonance imaging.

Authors:  Gunnar Erz; Stefanie Mangold; Erik Franzen; Claus D Claussen; Andreas M Niess; Christof Burgstahler; Ulrich Kramer
Journal:  Int J Cardiovasc Imaging       Date:  2012-06-22       Impact factor: 2.357

2.  Incremental prognostic value of the SYNTAX score to late gadolinium-enhanced magnetic resonance images for patients with stable coronary artery disease.

Authors:  Shingo Kato; Naka Saito; Hidekuni Kirigaya; Daiki Gyotoku; Naoki Iinuma; Yuka Kusakawa; Kohei Iguchi; Tatsuya Nakachi; Kazuki Fukui; Masaaki Futaki; Tae Iwasawa; Masataka Taguri; Kazuo Kimura; Satoshi Umemura
Journal:  Heart Vessels       Date:  2015-04-23       Impact factor: 2.037

3.  Can we still rely on the ECG for detecting past myocardial injury?

Authors:  Gautam G Lalani; Andrew M Kahn; Sanjiv M Narayan
Journal:  JACC Cardiovasc Imaging       Date:  2013-02-20

4.  Uncommon cause of ST-segment elevation in V1-V3: incremental value of cardiac magnetic resonance imaging.

Authors:  Enrico Fabris; Giorgio Morocutti; Gianfranco Sinagra; Alessandro Proclemer; Gaetano Nucifora
Journal:  Clin Res Cardiol       Date:  2014-04-27       Impact factor: 5.460

5.  Magnetic resonance estimates of the extent and heterogeneity of scar tissue in ICD patients with ischemic cardiomyopathy predict ventricular arrhythmia.

Authors:  Tawfiq Zeidan-Shwiri; Yuesong Yang; Ilan Lashevsky; Ehud Kadmon; Darren Kagal; Alexander Dick; Avishag Laish Farkash; Gideon Paul; Donsheng Gao; Mohammed Shurrab; David Newman; Graham Wright; Eugene Crystal
Journal:  Heart Rhythm       Date:  2015-01-09       Impact factor: 6.343

Review 6.  Cardiac MRI: a central prognostic tool in myocardial fibrosis.

Authors:  Bharath Ambale-Venkatesh; João A C Lima
Journal:  Nat Rev Cardiol       Date:  2014-10-28       Impact factor: 32.419

7.  Effect of angiotensin-converting enzyme inhibitors and receptor blockers on appropriate implantable cardiac defibrillator shock in patients with severe systolic heart failure (from the GRADE Multicenter Study).

Authors:  Wael A AlJaroudi; Marwan M Refaat; Robert H Habib; Laila Al-Shaar; Madhurmeet Singh; Rebecca Gutmann; Heather L Bloom; Samuel C Dudley; Patrick T Ellinor; Samir F Saba; Alaa A Shalaby; Raul Weiss; Dennis M McNamara; Indrani Halder; Barry London
Journal:  Am J Cardiol       Date:  2015-01-15       Impact factor: 2.778

8.  Prognostic implications of Q waves at presentation in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: An analysis of the HORIZONS-AMI study.

Authors:  Ioanna Kosmidou; Björn Redfors; Aaron Crowley; Bernard Gersh; Shmuel Chen; José M Dizon; Monica Embacher; Roxana Mehran; Ori Ben-Yehuda; Gary S Mintz; Gregg W Stone
Journal:  Clin Cardiol       Date:  2017-07-11       Impact factor: 2.882

9.  Complexity of scar and ventricular arrhythmias in dilated cardiomyopathy of any etiology: Long-term data from the SCARFEAR (Cardiovascular Magnetic Resonance Predictors of Appropriate Implantable Cardioverter-Defibrillator Therapy Delivery) Registry.

Authors:  Stefano Pedretti; Sara Vargiu; Matteo Baroni; Santo Dellegrottaglie; Barbara Lanzarin; Alberto Roghi; Angela Milazzo; Giuseppina Quattrocchi; Maurizio Lunati; Patrizia Pedrotti
Journal:  Clin Cardiol       Date:  2018-04-17       Impact factor: 2.882

10.  The association of parathyroid hormone with ESRD and pre-ESRD mortality in the Kidney Early Evaluation Program.

Authors:  Georges Saab; Andrew S Bomback; Samy I McFarlane; Suying Li; Shu-Cheng Chen; Peter A McCullough; Adam Whaley-Connell
Journal:  J Clin Endocrinol Metab       Date:  2012-10-12       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.